ClinicalTrials.gg
RecruitingNCT01365169Updated Jul 15, 2026

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

An interventional study of Exercise Intervention and Health Telemonitoring in Malignant Head and Neck Neoplasm, Malignant Neoplasm and Metastatic Malignant Neoplasm in the Neck, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started May 2011; still recruiting 15 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
590
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center — 8 open to participants now, 21 under way, 1 of them phase 3. Head and Neck Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
3rd of 56
590 · median 25
Started
2011
with 6 others
No phase
17 of 74
4 open now
Primary completion
2027-06
later than 12 of 20 live
Registered
42nd of 74
by date

Among the 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center, this one is the 3rd largest by planned enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2011, is one of 17 with no phase, reaches primary completion later than 12 of the 20 other live ones, and was the 42nd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

8 of the 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and overall survival. The purpose is to advance the evidence-base for incorporating objective assessment of Physical Activity (PA) in the context of performance status assessment in advanced cancer patients.

Read the detailed description

PRIMARY OBJECTIVES:

I. To explore the feasibility and acceptability in diverse samples of cancer patients of wireless collection and transmission of data for transfer into the open-source cyberinfrastructure (CI) called Cyberinfrastructure for Comparative Effectiveness Research (CYCORE).

OUTLINE: Patients are assigned to 1 of 4 arms.

ARM I (COLORECTAL CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a global positioning system (GPS) device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.

ARM II (HEAD AND NECK CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.

ARM III (HEAD AND NECK CANCER PATIENTS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.

ARM IV (CANCER SURVIVORS THAT ARE CURRENT/FORMER SMOKERS) (CLOSED TO ACCRUAL AS OF 01/30/14): Patients use a carbon monoxide (CO) monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.

PANCREATIC CANCER STUDY (PCS): Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.

Technological Approach to Performance Status (TAPS) Study: Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.

03

Conditions studied

  • Malignant Head and Neck Neoplasm
  • Malignant Neoplasm
  • Metastatic Malignant Neoplasm in the Neck
  • Metastatic Malignant Neoplasm in the Uterine Cervix
  • Pancreatic Adenocarcinoma
  • Pancreatic Neuroendocrine Carcinoma
  • Recurrent Colorectal Carcinoma
  • Stage I Colorectal Cancer AJCC v6 and v7
  • Stage I Hypopharyngeal Carcinoma AJCC v7
  • Stage I Major Salivary Gland Cancer AJCC v7
  • Stage I Nasopharyngeal Carcinoma AJCC v7
  • Stage I Oral Cavity Cancer AJCC v6 and v7
  • Stage I Oropharyngeal Carcinoma AJCC v6 and v7
  • Stage II Colorectal Cancer AJCC v7
  • Stage II Hypopharyngeal Carcinoma AJCC v6 and v7
  • Stage II Major Salivary Gland Cancer AJCC v7
  • Stage II Nasopharyngeal Carcinoma AJCC v7
  • Stage II Oral Cavity Cancer AJCC v6 and v7
  • Stage II Oropharyngeal Carcinoma AJCC v6 and v7
  • Stage IIA Colorectal Cancer AJCC v7
  • Stage IIB Colorectal Cancer AJCC v7
  • Stage IIC Colorectal Cancer AJCC v7
  • Stage III Colorectal Cancer AJCC v7
  • Stage III Hypopharyngeal Carcinoma AJCC v7
  • Stage III Laryngeal Cancer AJCC v6 and v7
  • Stage III Major Salivary Gland Cancer AJCC v7
  • Stage III Nasopharyngeal Carcinoma AJCC v7
  • Stage III Oral Cavity Cancer AJCC v6 and v7
  • Stage III Oropharyngeal Carcinoma AJCC v7
  • Stage IIIA Colorectal Cancer AJCC v7
  • Stage IIIB Colorectal Cancer AJCC v7
  • Stage IIIC Colorectal Cancer AJCC v7
  • Stage IV Colorectal Cancer AJCC v7
  • Stage IVA Colorectal Cancer AJCC v7
  • Stage IVA Hypopharyngeal Carcinoma AJCC v7
  • Stage IVA Laryngeal Cancer AJCC v7
  • Stage IVA Major Salivary Gland Cancer AJCC v7
  • Stage IVA Nasopharyngeal Carcinoma AJCC v7
  • Stage IVA Oral Cavity Cancer AJCC v6 and v7
  • Stage IVA Oropharyngeal Carcinoma AJCC v7
  • Stage IVB Colorectal Cancer AJCC v7
  • Stage IVB Hypopharyngeal Carcinoma AJCC v7
  • Stage IVB Laryngeal Cancer AJCC v7
  • Stage IVB Major Salivary Gland Cancer AJCC v7
  • Stage IVB Nasopharyngeal Carcinoma AJCC v7
  • Stage IVB Oral Cavity Cancer AJCC v6 and v7
  • Stage IVB Oropharyngeal Carcinoma AJCC v7
  • Metastatic or Locally Unresectable Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of any stage I - IV colorectal cancer or recurrent colorectal cancer (Arm 1)
  • Able to speak, read, and write in English (Pre-pilot phase, Arms 1-4)
  • Able to provide (Pre-pilot phase, Arms 1-4, PCS study)
  • Lives in the Houston area (Harris county or a contiguous county) (Pre-pilot phase)
  • (ECOG) status of 0 - 2, or self-reports being up and about more than 50% of waking hours and able to provide self-care (Arm 1)
  • Diagnosis of any of the following cancers: stage 1-4b oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b laryngeal; any unknown primary head and neck cancer with cervical that will be addressed with treatment to bilateral necks and mucosa; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating medical doctors (MDs) (Arms 2 and 3)
  • History of any cancer, other than non-melanoma skin cancer (Arm 4)
  • Admitted to being a current smoker or recent quitter upon admission to MD Anderson Cancer Center (MDACC) (Arm 4)
  • Has a valid home address and functioning home telephone number (Arm 4)
  • Lives in the Houston or surrounding area, or resides in this same area during the time period that coincides with this study (Arms 1-4)
  • Patients who will undergo curative pancreatectomy for pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, or pancreatic cysts (malignant or benign) (PCS study)
  • Fluent in English (PCS study)
  • Must have telephone access and agree to engage with research personnel using telephone (PCS study)
  • Diagnosis of a metastatic or locally unresectable solid tumor (TAPS study)
  • Fluent in English (TAPS study)
  • Age 18 years or older (TAPS study)
  • ECOG performance status score between 0-3 (TAPS study)

Exclusion criteria

Exclusion Criteria:

  • Major surgery in the past 8 weeks (Arms 1 and 4)
  • Self-reports hypertension that is not being monitored by a physician and is not being managed with either medication, observation, or lifestyle change (Pre-pilot phase, Arms 1-3)
  • Overt cognitive difficulty demonstrated by not being clearly oriented to time or person or place (Arms 1-4)
  • Orthopedic, neurologic, or musculoskeletal disability that would interfere with the functional task of standing on a weight scale (Pre-pilot phase, Arm 2)
  • Not currently receiving radiation treatment for a cancer listed in the arm-specific inclusion criteria (Arms 2 and 3)
  • Zubrod performance status > 2, or self-reports either not being up and about more than 50% of waking hours or unable to provide self-care (Arms 2 and 3)
  • Currently receiving treatment for a cancer other than those listed in the arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms 2 and 3)
  • History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) (Arm 3 only)
  • Active substance use disorder (diagnosed or strongly suspected) (Arm 4)
  • Currently enrolled in protocol 2014-0712 (PCS study)
  • No home access to internet (PCS study)
  • No home WiFi connection (PCS study)
  • During clinician's pre-surgical evaluation, presents with high risk for non-therapeutic resection related to cancer diagnosis (PCS study)
  • Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease ( functional class III or IV) (PCS study)
  • Recent fracture or acute musculoskeletal injury that precludes the ability to fully bear weight on all 4 limbs in order to participate in an exercise intervention (PCS study)
  • Poorly-controlled pain with a self-reported pain score of 7/10 at the time of enrollment (PCS study)
  • Myopathic or rheumatologic disease that impacts physical function (PCS study)
  • Has a pacemaker or other internal medical device, or reports being pregnant (PCS study)
  • Currently enrolled in protocol 2017-0198 (PCS study)
  • Demonstration of overt cognitive difficulty as demonstrated by not being clearly oriented to time or person or place (TAPS study)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
590 participants (estimated)

Study arms

  • Experimental
    Arm I (colorectal cancer patients)

    (CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a GPS device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.

    Other: Health Telemonitoring · Other: Questionnaire Administration

  • Experimental
    Arm II (head and neck cancer patients)

    (CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.

    Other: Health Telemonitoring · Other: Questionnaire Administration

  • Experimental
    Arm III (head and neck cancer patients)

    (CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.

    Other: Health Telemonitoring · Other: Questionnaire Administration

  • Experimental
    Arm IV (cancer survivors that are current/former smokers)

    (CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a CO monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.

    Other: Health Telemonitoring · Other: Questionnaire Administration

  • Experimental
    PCS (pancreatic surgery patients)

    Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.

    Behavioral: Exercise Intervention · Other: Health Telemonitoring · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Experimental
    TAPS (Technological Approach to Performance Status)

    Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.

    Other: Health Telemonitoring

Interventions

  • BehavioralExercise Intervention

    Participate in walking and/or strengthening program

  • OtherHealth Telemonitoring

    Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone

  • OtherHealth Telemonitoring

    Use accelerometers, blood pressure monitor, weight scale, and smart phone

  • OtherHealth Telemonitoring

    Use smart phone

  • OtherHealth Telemonitoring

    Use CO monitor and smart phone

  • OtherHealth Telemonitoring

    Use Fitbit, weight scale and iPhone- or web-based app for self-reported data

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherHealth Telemonitoring

    Use Fitbit and Actigraph

06

What researchers measure

Primary outcomes

  1. Study completion (defined as completing the final assessment)

    Time frame: Up to 7 months after baseline

  2. Physical Activity (PA) Assessment

    PA will be measured by two different devices, (1) a consumer-grade wrist-worn device that collects continuous PA data (Fitbit), and (2) a research-grade, hip-worn accelerometer (Actigraph)

    Time frame: Up to 7 days

  3. ECOG Performance Status

    Eastern Cooperation Oncology Group (ECOG) is a 6-point performance status scale used to assess performance using PA as a key indicator (e.g., 0 = fully active, 2 = up and about more than 50% of walking hours, 5 = dead) Performance status will be assessed per usual clinical practice and will be recorded in the medical record.

    Time frame: Up to 2 weeks

Secondary outcomes

  1. Correlation between PA data from the Actigraph and Fitbit

    Association between PA measured using a Fitbit and PA measured using Actigraph

    Time frame: Up to 7 days

  2. Correlation between patients' ECOG performance status scores and PA data

    Association between performance status (PS) assesses by the patient's medical oncologist, and PA data

    Time frame: Up to 7 days

  3. Correlation between PA data and Overall Survivor (OS)

    Association between Physical Activity (PA) data and the Overall Survivor (OS) rate

    Time frame: Up to 7 days

  4. Accrual of Diverse Sample of Cancer-Patients

    Time frame: Up to 2 weeks

  5. Retention of using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales) among participants.

    Time frame: Up to 2 weeks

  6. Acceptability of using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales) among participants.

    Time frame: Up to 2 weeks

  7. Participants ability to activate, set-up, and use the home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales).

    Time frame: Up to 2 weeks

  8. Adherence to procedures for home-based health monitor devices activation (e.g. Fitbit, Actigraph, CO monitor, weight scales) self-monitoring (e.g. PA, weight), and self-reported data capture by the devices.

    Time frame: Up to 2 weeks

  9. Successful upload of data from the home-based health monitor devices to the Cyberinfrastructure for Comparative effectiveness Research (CYCORE) for future analysis.

    Time frame: Up to 2 weeks

  10. CYCORE Data availability for clinicians and researchers in order to be able to daily monitor patients using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales).

    Time frame: Up to 2 weeks

07

Study locations

1 of 1 sites recruiting
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Susan K. Peterson · Contact713-792-8267
    • Susan K. Peterson · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2011 (actual). Primary completion is estimated for Jun 2027, 193 months after the start.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 193 months is above that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2011
First posted
Jun 3, 2011
StartActual
May 25, 2011
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01365169
Responsible party
Sponsor
First posted
Jun 3, 2011
Start date
May 25, 2011
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Susan Peterson
Contact
speterso@mdanderson.org
713-792-8267
Susan K Peterson
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion